Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Valentina Tabanelli et al.|The Lancet Haematology|2025Cited by 6
Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiencesBernardo Rossini, Attilio Guarini, Nicola Cecchi et al.|Drugs in Context|2014Cited by 3
Corrigendum: Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiencesBernardo Rossini, Attilio Guarini, Giovanna Palumbo et al.|Drugs in Context|2024Cited by 3
<i>TP53</i>, <i>CD36</i> Mutations and <i>CDKN2A</i> Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 TrialRiccardo Moia, Carlo Visco, Maria Elena Carazzolo et al.|Blood|2024Cited by 3